サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467832

黄斑変性症治療市場レポート：タイプ別、病期別、投与経路別、エンドユーザー別、地域別、2024～2032年

Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 137 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
黄斑変性症治療市場レポート：タイプ別、病期別、投与経路別、エンドユーザー別、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

黄斑変性症治療の世界市場規模は2023年に94億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて5.5%の成長率（CAGR）を示し、2032年までに154億米ドルに達すると予測しています。

黄斑変性症は神経変性眼疾患であり、眼を侵し、視野の中心部のぼやけや視力低下を引き起こします。視野の盲点、視覚の歪み、低照度下での視力低下を特徴とします。黄斑変性症の治療法としては、血管新生阻害薬、光線力学的レーザー治療、コンタクトレンズ、移行レンズなどが一般的に使用されています。レーザー治療では、眼球の患部に専用のコンタクトレンズを挿入し、血管とともにレーザーで密封します。血管新生阻害薬は、血管の閉塞や漏れを防ぐために使用されます。黄斑変性症治療を適時に行うことで、視力を向上させ、慢性失明のリスクを最小限に抑えることができます。

黄斑変性症治療の市場動向：

加齢黄斑変性と肥満の増加が市場成長を促進する主要要因の1つです。食事パターンの変化や座りがちなライフスタイルの増加が黄斑変性症の発症につながっています。さらに、スマートフォン、ノートパソコン、テレビの利用が増え、長時間、過度なスクリーンタイムを過ごすようになっていることも、この疾患の発生に影響を与えています。さらに、異常な血管の発達を防ぐためにアデノ随伴ウイルス（AAV）を体内に注入する網膜遺伝子治療の市場開拓が、市場の成長を後押ししています。これに伴い、医療インフラの大幅な改善が市場成長にプラスの影響を与えています。その他の要因としては、革新的で効果的な医薬品を開発するための広範な研究開発活動や、公衆衛生を促進するためのさまざまな政府イニシアチブの実施などが挙げられ、市場の成長を後押しすると予想されます。

本レポートで扱う主要質問

  • 2023年の世界の黄斑変性症治療市場規模は？
  • 2024～2032年の世界の黄斑変性症治療市場の予想成長率は？
  • 黄斑変性症治療の世界市場を牽引する主要因は何か？
  • COVID-19が世界の黄斑変性症治療市場に与えた影響は？
  • 黄斑変性症治療世界市場のタイプ別区分は？
  • 黄斑変性症治療世界市場の病期別内訳は？
  • 投与経路別の黄斑変性症治療世界市場の内訳は？
  • エンドユーザー別の黄斑変性症治療世界市場の内訳は？
  • 黄斑変性症治療の世界市場における主要地域は？
  • 黄斑変性症治療の世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 黄斑変性症治療の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 乾性
  • 湿性

第7章 市場内訳：病期別

  • 全期
  • 中期
  • 後期

第8章 市場内訳：投与経路別

  • 静脈内
  • 硝子体内

第9章 市場内訳：エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Aerie Pharmaceuticals Inc.
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche Ltd
    • Iveric Bio Inc.
    • Novartis AG
    • Panoptica
    • Pfizer Inc.
    • Phio Pharmaceuticals
    • Regeneron Pharmaceuticals Inc.
    • Regenxbio Inc.
    • Santen Pharmaceutical Co. Ltd.
図表

List of Figures

  • Figure 1: Global: Macular Degeneration Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Macular Degeneration Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Macular Degeneration Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Macular Degeneration Treatment Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Macular Degeneration Treatment Market: Breakup by Stage of Disease (in %), 2023
  • Figure 6: Global: Macular Degeneration Treatment Market: Breakup by Route of Administration (in %), 2023
  • Figure 7: Global: Macular Degeneration Treatment Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Macular Degeneration Treatment Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Macular Degeneration Treatment (Dry Age-related Macular Degeneration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Macular Degeneration Treatment (Dry Age-related Macular Degeneration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Macular Degeneration Treatment (Wet Age-related Macular Degeneration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Macular Degeneration Treatment (Wet Age-related Macular Degeneration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Macular Degeneration Treatment (Early Stage) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Macular Degeneration Treatment (Early Stage) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Macular Degeneration Treatment (Intermediate Stage) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Macular Degeneration Treatment (Intermediate Stage) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Macular Degeneration Treatment (Late Stage) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Macular Degeneration Treatment (Late Stage) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Macular Degeneration Treatment (Intravenous Route) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Macular Degeneration Treatment (Intravenous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Macular Degeneration Treatment (Intravitreal Route) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Macular Degeneration Treatment (Intravitreal Route) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Macular Degeneration Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Macular Degeneration Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Macular Degeneration Treatment (Ambulatory Surgical Center) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Macular Degeneration Treatment (Ambulatory Surgical Center) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Macular Degeneration Treatment (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Macular Degeneration Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: North America: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: North America: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: United States: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: United States: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Canada: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Canada: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Asia-Pacific: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Asia-Pacific: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: China: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: China: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Japan: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Japan: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: India: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: India: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: South Korea: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: South Korea: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Australia: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Australia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Indonesia: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Indonesia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Europe: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Europe: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Germany: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Germany: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: France: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: France: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: United Kingdom: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: United Kingdom: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Italy: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Italy: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Spain: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Spain: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Russia: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Russia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Latin America: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Latin America: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Brazil: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Brazil: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Mexico: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Mexico: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Middle East and Africa: Macular Degeneration Treatment Market: Breakup by Country (in %), 2023
  • Figure 77: Middle East and Africa: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Global: Macular Degeneration Treatment Industry: SWOT Analysis
  • Figure 79: Global: Macular Degeneration Treatment Industry: Value Chain Analysis
  • Figure 80: Global: Macular Degeneration Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Macular Degeneration Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Macular Degeneration Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Macular Degeneration Treatment Market Forecast: Breakup by Stage of Disease (in Million US$), 2024-2032
  • Table 4: Global: Macular Degeneration Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 5: Global: Macular Degeneration Treatment Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Macular Degeneration Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Macular Degeneration Treatment Market: Competitive Structure
  • Table 8: Global: Macular Degeneration Treatment Market: Key Players
目次
Product Code: SR112024A5118

The global macular degeneration treatment market size reached US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.5% during 2024-2032.

Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions. Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels. Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.

Macular Degeneration Treatment Market Trends:

The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration. Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth. In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global macular degeneration treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, stage of disease, route of administration and end user.

Breakup by Type:

Dry Age-related Macular Degeneration

Wet Age-related Macular Degeneration

Breakup by Stage of Disease:

Early Stage

Intermediate Stage

Late Stage

Breakup by Route of Administration:

Intravenous Route

Intravitreal Route

Breakup by End User:

Hospitals

Ambulatory Surgical Center

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.

Key Questions Answered in This Report

  • 1. What was the size of the global macular degeneration treatment market in 2023?
  • 2. What is the expected growth rate of the global macular degeneration treatment market during 2024-2032?
  • 3. What are the key factors driving the global macular degeneration treatment market?
  • 4. What has been the impact of COVID-19 on the global macular degeneration treatment market?
  • 5. What is the breakup of the global macular degeneration treatment market based on the type?
  • 6. What is the breakup of the global macular degeneration treatment market based on the stage of disease?
  • 7. What is the breakup of the global macular degeneration treatment market based on the route of administration?
  • 8. What is the breakup of the global macular degeneration treatment market based on the end user?
  • 9. What are the key regions in the global macular degeneration treatment market?
  • 10. Who are the key players/companies in the global macular degeneration treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Macular Degeneration Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Dry Age-related Macular Degeneration
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Wet Age-related Macular Degeneration
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Stage of Disease

  • 7.1 Early Stage
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intermediate Stage
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Late Stage
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Intravenous Route
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Intravitreal Route
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgical Center
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Aerie Pharmaceuticals Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Bausch Health Companies Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bayer AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche Ltd
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Iveric Bio Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Novartis AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Panoptica
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Phio Pharmaceuticals
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Regeneron Pharmaceuticals Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Regenxbio Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Santen Pharmaceutical Co. Ltd.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis